A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 216 participants.

Also called NCT07109700

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 216 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07109700
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07109700. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2026-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
Intervention (Drug)
HDM1005 1
Intervention (Drug)
HDM1005 2
Intervention (Drug)
HDM1005 3
Intervention (Drug)
HDM1005 4
Intervention (Drug)
Placebo
Intervention (Drug)
Dulaglutide 1.5 MG
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07109700
Content hash
6510dea03a5e6f13bfd001262b66bffe88ca11ad6d5166189383628f06753efe